211 related articles for article (PubMed ID: 26728985)
21. Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA.
Boriani G; Merino J; Wright DJ; Gadler F; Schaer B; Landolina M
Europace; 2018 Dec; 20(12):1882-1897. PubMed ID: 29757390
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis.
Sun WP; Li CL; Guo JC; Zhang LX; Liu R; Zhang HB; Zhang L
Heart Fail Rev; 2016 Jul; 21(4):447-53. PubMed ID: 27043219
[TBL] [Abstract][Full Text] [Related]
23. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF.
Wilcox JE; Fonarow GC; Zhang Y; Albert NM; Curtis AB; Gheorghiade M; Heywood JT; Mehra MR; O'Connor CM; Reynolds D; Walsh MN; Yancy CW
Circ Heart Fail; 2014 Jan; 7(1):146-53. PubMed ID: 24178311
[TBL] [Abstract][Full Text] [Related]
24. Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience.
Kutyifa V; Geller L; Bogyi P; Zima E; Aktas MK; Ozcan EE; Becker D; Nagy VK; Kosztin A; Szilagyi S; Merkely B
Eur J Heart Fail; 2014 Dec; 16(12):1323-30. PubMed ID: 25379962
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.
Maniadakis N; Ekman M; Calvert MJ; Freemantle N; Karamalis M; Vardas P
Europace; 2011 Nov; 13(11):1597-603. PubMed ID: 21821852
[TBL] [Abstract][Full Text] [Related]
26. Remote Monitoring of Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy and Permanent Pacemakers: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2018; 18(7):1-199. PubMed ID: 30443279
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data.
Shah D; Lu X; Paly VF; Tsintzos SI; May DM
J Med Econ; 2020 Jul; 23(7):690-697. PubMed ID: 32207659
[No Abstract] [Full Text] [Related]
29. Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy.
Barra S; Looi KL; Gajendragadkar PR; Khan FZ; Virdee M; Agarwal S
Europace; 2016 Aug; 18(8):1187-93. PubMed ID: 26566940
[TBL] [Abstract][Full Text] [Related]
30. The mortality analysis of primary prevention patients receiving a cardiac resynchronization defibrillator (CRT-D) or implantable cardioverter-defibrillator (ICD) according to guideline indications in the improve SCA study.
Ching CK; Hsieh YC; Liu YB; Rodriguez DA; Kim YH; Joung B; Singh B; Huang D; Hussin A; Chasnoits AR; O'Brien JE; Cerkvenik J; Lexcen D; Van Dorn B; Zhang S
J Cardiovasc Electrophysiol; 2021 Aug; 32(8):2285-2294. PubMed ID: 34216069
[TBL] [Abstract][Full Text] [Related]
31. Inverse Relationship of Blood Pressure to Long-Term Outcomes and Benefit of Cardiac Resynchronization Therapy in Patients With Mild Heart Failure: A Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Long-Term Follow-Up Substudy.
Biton Y; Moss AJ; Kutyifa V; Mathias A; Sherazi S; Zareba W; McNitt S; Polonsky B; Barsheshet A; Brown MW; Goldenberg I
Circ Heart Fail; 2015 Sep; 8(5):921-6. PubMed ID: 26179186
[TBL] [Abstract][Full Text] [Related]
32. Reduced long-term overall mortality in heart failure patients with prolonged QRS treated with CRT combined with ICD vs. heart failure patients with narrow QRS treated with ICD only.
Palmisano P; Accogli M; Pisanò EC; Zaccaria M; De Blasi S; Ponzetta MA; Valsecchi S; Milanese G; Lauretti M; Magliari F
Europace; 2016 Sep; 18(9):1374-82. PubMed ID: 26612878
[TBL] [Abstract][Full Text] [Related]
33. Impact of community wealth on use of cardiac-resynchronization therapy with defibrillators for heart failure patients.
Farmer SA; Tuohy EJ; Small DS; Wang Y; Groeneveld PW
Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):798-807. PubMed ID: 23093561
[TBL] [Abstract][Full Text] [Related]
34. Temporal Influence of Heart Failure Hospitalizations Prior to Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator on Subsequent Outcome in Mild Heart Failure Patients (from MADIT-CRT).
Lee AY; Moss AJ; Ruwald MH; Kutyifa V; McNitt S; Polonsky B; Zareba W; Ruwald AC
Am J Cardiol; 2015 May; 115(10):1423-7. PubMed ID: 25817576
[TBL] [Abstract][Full Text] [Related]
35. Cardiac resynchronization therapy with and without implantable cardioverter-defibrillator.
Shimizu A
Circ J; 2009 Jun; 73 Suppl A():A29-35. PubMed ID: 19474508
[TBL] [Abstract][Full Text] [Related]
36. Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States.
Patel N; Viles-Gonzalez J; Agnihotri K; Arora S; Patel NJ; Aneja E; Shah M; Badheka AO; Pothineni NV; Kancharla K; Mulpuru S; Noseworthy PA; Kusumoto F; Cha YM; Deshmukh AJ
J Cardiovasc Electrophysiol; 2018 Oct; 29(10):1425-1435. PubMed ID: 30016005
[TBL] [Abstract][Full Text] [Related]
37. Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.
Borne RT; Masoudi FA; Curtis JP; Zipse MM; Sandhu A; Hsu JC; Peterson PN
JAMA Netw Open; 2021 Jan; 4(1):e2035470. PubMed ID: 33496796
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
[TBL] [Abstract][Full Text] [Related]
39. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE).
Gold MR; Daubert JC; Abraham WT; Hassager C; Dinerman JL; Hudnall JH; Cerkvenik J; Linde C
Circ Arrhythm Electrophysiol; 2013 Dec; 6(6):1163-8. PubMed ID: 24125796
[TBL] [Abstract][Full Text] [Related]
40. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK.
Caro JJ; Guo S; Ward A; Chalil S; Malik F; Leyva F
Curr Med Res Opin; 2006 Jun; 22(6):1171-9. PubMed ID: 16846550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
